While IL-10 is known to play a protective role in MS [26], we have previously observed that the level of MBP-induced IL-5 correlated positively with disease activity [18], and that T cells from secondary progressive MS patients have a higher expression of IL-5 than those of RRMS patients [27]. This evidence concerns the gene IL10 and myeloid sarcoma.